Business Context and Reporting Period
Inhibikase Therapeutics, Inc. is a clinical-stage pharmaceutical company developing protein kinase inhibitors for Parkinson’s disease, Parkinson’s-related disorders, multiple system atrophy (MSA), and stable-phase chronic myelogenous leukemia (SP-CML). This Form 10-Q covers the three and six months ended June 30, 2023, with unaudited interim financial statements.
- IkT-148009: Phase 2 Parkinson’s disease program initiated in January 2023; 22 of 35 planned sites were screening and enrolling patients, and the first patient had completed the 12-week regimen.
- MSA: The company opened its IND in March 2023 and was conducting supporting animal studies. A Phase 2 study was planned subject to study results and available resources.
- IkT-001Pro: The 501 trial was evaluating dose equivalence to imatinib mesylate in healthy volunteers. Four dose-escalation cohorts had completed, and 31 subjects had completed the dose-equivalence phase as of the filing date.
Financial Position and Results
| Metric | Three Months Ended June 30, 2023 | Six Months Ended June 30, 2023 | Comparable Prior Period |
|---|
| Grant revenue | $116,410 | $180,931 | $6,552 and $52,583 |
| Research and development expense | $4.54 million | $7.39 million | $2.98 million and $6.00 million |
| SG&A expense | $1.78 million | $3.71 million | $1.66 million and $3.33 million |
| Loss from operations | $(6.20) million | $(10.92) million | $(4.64) million and $(9.28) million |
| Net loss | $(5.78) million | $(10.26) million | $(4.64) million and $(9.28) million |
| Basic and diluted loss per share | $(1.11) | $(2.09) | $(1.10) and $(2.20) |
- Revenue consisted entirely of federal research grant revenue; the company has generated no commercial product sales.
- Operating expenses substantially exceeded revenue. The filing does not present a meaningful gross margin because the company is a development-stage business with no product revenue.
- Second-quarter R&D expense increased 52.1% year over year, primarily because of the ongoing Phase 2a Parkinson’s disease trial. Six-month R&D expense increased 23.2%.
- Six-month SG&A expense increased 11.2% year over year. Interest income increased to $661,606 for the six months, reflecting investment of cash in U.S. Treasury securities and money market instruments.
Cash Flow, Liquidity, and Capitalization
| Balance or Cash Flow | June 30, 2023 | December 31, 2022 |
|---|
| Cash and cash equivalents | $1.91 million | $7.19 million |
| Marketable securities | $19.03 million | $15.86 million |
| Working capital | $19.25 million | Not clearly provided in the filing text |
| Total liabilities | $2.88 million | $3.90 million |
| Accumulated deficit | $(58.13) million | $(47.87) million |
- Net cash used in operating activities was $10.54 million for the six months ended June 30, 2023, compared with $8.29 million in the prior-year period.
- Net cash used in investing activities was $3.29 million, reflecting $18.68 million of purchases of marketable securities, partly offset by $15.41 million of maturities.
- Net cash provided by financing activities was $8.54 million, primarily from the January 2023 offering of common stock and pre-funded warrants, net of issuance costs.
- Cash and cash equivalents declined by $5.28 million during the first six months, from $7.19 million to $1.91 million. Including marketable securities, the company held approximately $20.94 million of cash and short-term investments at June 30, 2023.
- The company had no material conventional debt disclosed. Lease liabilities totaled $297,937, including $147,966 current and $149,971 non-current.
- Management estimated that existing working capital would fund normal operations into the fourth quarter of 2024, but stated that additional capital will be needed and that the estimate depends on assumptions that may prove inaccurate.
Material Changes Versus the Prior Comparable Period
- Six-month net loss increased by $975,204, or 10.5%, to $10.26 million, despite $661,606 of interest income.
- Six-month operating loss increased by $1.64 million, or 17.6%, primarily due to higher clinical development spending.
- Grant revenue increased 244.1% for the first six months but remained immaterial relative to operating costs and was concentrated in MSA preclinical activities.
- The company raised approximately $8.6 million of net proceeds in January 2023 through equity and warrant-related securities.
- A one-for-six reverse stock split became effective June 30, 2023. Share and per-share information in the filing was retroactively adjusted for the split.
- On July 17, 2023, Nasdaq notified the company that it had regained compliance with the minimum bid price rule.
Guidance, Outlook, Risks, and Unusual Items
- The company expects research and development expenses and losses to increase as clinical programs advance. No revenue or profitability guidance was provided.
- Management expects to seek additional equity, debt, grant, licensing, or collaboration funding. Failure to obtain financing could require delaying, reducing, or discontinuing clinical development.
- The financial statements were prepared on a going-concern basis. The company has recurring losses, negative operating cash flow, no approved commercial products, and an accumulated deficit of $58.13 million.
- Key development risks include clinical-trial enrollment and execution, safety and efficacy outcomes, regulatory approval, manufacturing and supply-chain dependence, intellectual-property protection, and the possibility that early clinical or animal results will not predict later outcomes.
- All revenue was derived from the U.S. government through research grants, creating significant revenue concentration.
- The company reported no material litigation and no off-balance-sheet arrangements. It identified macroeconomic, geopolitical, financial-institution, cybersecurity, and COVID-19-related risks.
Important Facts for Investors to Verify
- Whether the Parkinson’s Phase 2 trial remains on schedule, reaches its planned site and enrollment targets, and produces clinically meaningful safety and efficacy results.
- The timing, scope, and financing of any planned MSA Phase 2 program and the outcome of supporting animal studies.
- Completion and results of the IkT-001Pro 501 trial, including any additional cohort evaluating equivalence to 600 mg imatinib mesylate and the FDA’s position on the proposed 505(b)(2) pathway.
- The company’s actual cash burn and remaining runway relative to the fourth-quarter 2024 estimate, particularly if additional financing is delayed or clinical spending increases.
- Potential dilution from outstanding warrants, pre-funded warrants, and options; 3,973,503 shares were reserved for outstanding options and warrants at June 30, 2023.
- Continued Nasdaq compliance and the company’s ability to raise capital on acceptable terms.
